This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
What Is KPV?
KPV is a tripeptide consisting of three amino acids — lysine, proline, and valine — derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a 13-amino acid neuropeptide with well-documented anti-inflammatory properties, but its full-length form also activates melanocortin receptors involved in pigmentation, appetite, and sexual function. KPV retains the anti-inflammatory activity of alpha-MSH while lacking the melanocortin receptor binding that causes the broader hormonal effects.
This dissociation of anti-inflammatory activity from melanocortin receptor signaling makes KPV an attractive research target. It is one of the smallest bioactive peptides studied for inflammation, and its simplicity has drawn interest for potential oral and topical applications.
Mechanism of Action
KPV's anti-inflammatory mechanism centers on direct intracellular signaling rather than receptor-mediated pathways:
- NF-kB inhibition: KPV enters cells and directly inhibits nuclear factor kappa-B (NF-kB) activation — the master transcription factor driving inflammatory gene expression. It does this by interacting with components of the NF-kB signaling cascade, preventing nuclear translocation and subsequent transcription of pro-inflammatory cytokines.
- Inflammatory cytokine suppression: By blocking NF-kB, KPV reduces production of TNF-alpha, IL-1beta, IL-6, and other pro-inflammatory mediators.
- PepT1 transporter uptake: A key finding by Dalmasso et al. (2008) demonstrated that KPV is actively transported into intestinal epithelial cells via the PepT1 transporter. This means KPV may have preferential uptake in the gut when administered orally — a rare and therapeutically significant property for an anti-inflammatory peptide.
- Immune cell modulation: KPV suppresses inflammatory activation of macrophages, dendritic cells, and T-cells, reducing tissue-damaging immune responses without broadly suppressing immune function.
Research Findings
The most compelling research on KPV comes from intestinal inflammation models. Dalmasso et al. published multiple studies demonstrating that KPV, administered orally in animal models of colitis, significantly reduced intestinal inflammation, mucosal damage, and inflammatory cytokine levels. In DSS-induced colitis models (a standard model for inflammatory bowel disease), oral KPV reduced disease activity index scores and histological inflammation comparable to conventional anti-inflammatory agents.
Additional research has shown KPV's anti-inflammatory effects in skin inflammation models, where it reduced inflammatory markers in keratinocytes, and in wound healing contexts, where it accelerated resolution of the inflammatory phase. A nanoparticle delivery study demonstrated that KPV loaded into hyaluronic acid nanoparticles provided enhanced targeted delivery to inflamed colonic tissue.
Dosing and Administration
- Oral: 200-500 mcg per day — the PepT1 transporter-mediated uptake provides a rationale for oral use, particularly for gut-targeted applications
- Subcutaneous: 200-500 mcg per day for systemic anti-inflammatory effects
- Topical: Applied in compounded creams for localized skin inflammation
- Cycle length: Variable; commonly used in 4-8 week protocols
The Bottom Line
KPV is a compelling anti-inflammatory tripeptide with a well-characterized mechanism (NF-kB inhibition) and particularly interesting data for intestinal inflammation. Its oral bioavailability via PepT1 transport is a significant advantage for gut applications. However, research remains preclinical — no human clinical trials have been completed for any indication. It is not approved for any clinical use and should be considered an experimental research peptide.